Cargando…

PB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS

Detalles Bibliográficos
Autores principales:	Navickas, A., González, J., Rivas, M. M., Clavijo, M., Carnelutto, N., Funes, M. E., Mela Osorio, M. J., Mariano, R., Rapan, M. L., Moirano, M., Rey, I., Cranco, S., Giunta, J. E., Ramirez, R., Castro, M. B., Enrico, A., Gimenez Conca, A., Belli, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429148/ http://dx.doi.org/10.1097/01.HS9.0000850168.39267.76

Ejemplares similares

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
por: Ruhnke, Leo, et al.
Publicado: (2023)

S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
por: Rücker, Frank G, et al.
Publicado: (2023)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
por: Dokal, Arran, et al.
Publicado: (2023)

Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias
por: Lipka, D B, et al.
Publicado: (2016)

Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience
por: Weinbergerová, Barbora, et al.
Publicado: (2023)

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
por: Rosenberg, Mara W., et al.
Publicado: (2020)

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase
por: Weisberg, Ellen L., et al.
Publicado: (2017)

Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia
por: Weisberg, Ellen, et al.
Publicado: (2020)

Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain
por: Arenaza, Ainhoa, et al.
Publicado: (2019)

Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
por: Garitano-Trojaola, Andoni, et al.
Publicado: (2021)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
por: Lee, Julia S., et al.
Publicado: (2023)

Dose intensity in cancer chemotherapy.
por: Dodwell, D. J., et al.
Publicado: (1990)

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
por: Seipel, Katja, et al.
Publicado: (2018)

Midostaurin-Related Interstitial Lung Injury in FLT3(+) Acute Myeloid Leukemia Post-Allogeneic Transplant
por: Vaidya, Poorva, et al.
Publicado: (2019)

The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report
por: He, Shujiao, et al.
Publicado: (2022)

Intensive Cytotoxic Chemotherapy
por: Bagshawe, K. D.
Publicado: (1971)

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
por: Maziarz, Richard T., et al.
Publicado: (2020)

PB1890: TRIAL IN PROGRESS: A PHASE II STUDY OF MIDOSTAURIN COMBINED WITH INDUCTION/CONSOLIDATION CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN PEDIATRIC PATENTS WITH FLT3-MUTATED ACUTE MYELOID LEUKEMIA
por: Reinhardt, Dirk, et al.
Publicado: (2023)

Midostaurin: an emerging treatment for acute myeloid leukemia patients
por: Gallogly, Molly Megan, et al.
Publicado: (2016)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023)

P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer.
por: Ferguson, J. E., et al.
Publicado: (1993)

Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy
por: Weisberg, Ellen, et al.
Publicado: (2017)

Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3
por: Lu, Hao, et al.
Publicado: (2022)

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial
por: Sierra, Jorge, et al.
Publicado: (2023)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Effect of leaving chronic oral foci untreated on infectious complications during intensive chemotherapy
por: Schuurhuis, J M, et al.
Publicado: (2016)

Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
por: Ayala, Rosa, et al.
Publicado: (2022)

Multiplexed single‐cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells
por: Rörby, Emma, et al.
Publicado: (2021)

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
por: Perl, Alexander E., et al.
Publicado: (2022)

Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
por: Menna, Pierantonio, et al.
Publicado: (2023)

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
por: Aikawa, Tomoya, et al.
Publicado: (2020)

P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
por: Cremer, Anjali, et al.
Publicado: (2023)

Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy
por: Karol, Seth E., et al.
Publicado: (2021)

High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study
por: Cattaneo, Chiara, et al.
Publicado: (2022)

Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity
por: Fernando, I.N., et al.
Publicado: (2023)

Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML
por: Cremer, Anjali, et al.
Publicado: (2023)

Intensity-Modulated and Image-Guided Radiotherapy in Patients with Locally Advanced Inoperable Pancreatic Cancer after Preradiation Chemotherapy
por: Sinn, M., et al.
Publicado: (2014)

P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING
por: Nanni, Jacopo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4j66o88g5bvmvm07b1vdhsh0ej